The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Vincerx Pharma announces early results for VIP943 and VIP236 in Phase 1 studies targeting hard-to-treat cancers, with complete responses seen in AML and HR-MDS patients and encouraging disease ...

Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus ...

Find latest healthcare news from every corner of the globe at Reuters.com, your online source for breaking international news ...

The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable ...

Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada.

Citi lowered the firm’s price target on Royalty Pharma (RPRX) to $40 from $60 and keeps a Buy rating on the shares following a transfer ...

Contract Development and Manufacturing Organization (CDMO): Piramal Pharma said that targeted business development efforts ...

Oslo, Norway, 24 October 2024 Vistin Pharma ASA will release its third quarter and YTD 2024 results on Thursday 31st of October 2024. Vistin Pharma will host a conference call for all shareholders and ...